The page below is a sample from the LabCE course HER2 Testing in Breast Cancer. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about HER2 Testing in Breast Cancer (online CE course) »
How to Subscribe
Histology CE Package$65 Add to cart

Herceptin® (Trastuzumab)

Herceptin®, known generically as trastuzumab, is a product of Genentech, with corporate headquarters located in San Francisco, Califiornia. Trastuzumab is a humanized monoclonal antibody that binds to the HER2 receptor. It has been shown to improve response rates, time to progression, and survival. It was approved in 1998 by the United States (US) Food and Drug Administration (FDA) for the treatment of metastatic disease.